SEP 24, 2014 10:00 AM PDT

Keynote, The Promises and Challenges of Next-Generation Therapeutics

Speaker
  • CEO, Warp Drive Bio, Erving Professor of Chemistry, Harvard University
    Biography
      Gregory Verdine is a pioneer in the field of chemical biology, having served as the Erving Professor of Chemistry at Harvard University for the past 25 years. Among many scientific accomplishments, he discovered the molecular mechanism of epigenetic DNA methylation and developed a new class of therapeutics termed stapled peptides, which are currently in clinical development. In addition to Warp Drive, Greg has co-founded multiple biotechnology companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics. In 2009, he joined Third Rock Ventures as a venture partner. Verdine holds a Ph.D. in chemistry from Columbia University, a B.S. in chemistry from St. Joseph's University, and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School. His talk will be on the discovery and synthesis of natural product-like compounds.

    Abstract

    The ever-quickening pace of breathtaking advances in our understanding of disease biology has implicitly promised a profusion of drugs that will dramatically improve human health and well-being. Realization of this promise remains frustratingly elusive. Where are all the new drugs? We contend that a major contributing factor is the limitations in target scope of the two well-establish drug modalities, namely small molecules and protein therapeutics. Addressing this targetability gap will require the discovery and development of entirely new structural classes of drugs and the pioneering of new strategies for finding them. Any fundamentally new class of drug introduces discovery challenges that fall outside the hard-won risk-mitigation paradigms for established classes of drugs, hence the reluctance of pharma, biotech and even the investment community to fully embrace next-generation therapeutic modalties. Learning how to navigate these challenges will therefore fall disproportionately to the academic community, and will not be easy or happen quickly. That said, recent developments in the field of next-generation therapeutics give reason to be cautiously optimistic.


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    Loading Comments...
    Show Resources